Press Releases | Investors | Savara Inc.

June 28, 2024

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

June 26, 2024

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

June 25, 2024

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

May 29, 2024

Savara to Present at the Jefferies Global Healthcare Conference

May 19, 2024

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

May 16, 2024

Savara Announces New Employment Inducement Grant

May 09, 2024

Savara Reports First Quarter 2024 Financial Results and Provides Business Update

May 07, 2024

Savara to Present at the Citizens JMP Life Sciences Conference

April 08, 2024

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

March 22, 2024

Savara Announces New Employment Inducement Grant

March 07, 2024

Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update

March 06, 2024

Savara to Present at the Barclays 26th Annual Global Healthcare Conference

February 02, 2024

Savara Announces New Employment Inducement Grant

January 31, 2024

Savara to Present at Two Upcoming Healthcare Conferences

December 21, 2023

Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

December 20, 2023

Savara Added to the NASDAQ Biotechnology Index

December 15, 2023

Savara Announces New Employment Inducement Grant

November 21, 2023

Savara to Present at the Piper Sandler 35th Annual Healthcare Conference

November 09, 2023

Savara Reports Third Quarter Financial Results and Provides Business Update

November 08, 2023

Savara to Present at the Jefferies London Healthcare Conference

October 06, 2023

Savara Announces New Employment Inducement Grant

September 05, 2023

Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 10, 2023

Savara Reports Second Quarter Financial Results and Provides Business Update

August 04, 2023

Savara Announces New Employment Inducement Grant

July 13, 2023

Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

June 26, 2023

Savara Added to Russell 3000® Index

June 26, 2023

Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

June 02, 2023

Savara to Present at the Jefferies Healthcare Conference

May 15, 2023

Savara Reports First Quarter Financial Results and Provides Business Update

May 05, 2023

Savara Announces New Employment Inducement Grant

March 31, 2023

Savara Announces New Employment Inducement Grant

March 30, 2023

Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update

March 06, 2023

Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference

February 28, 2023

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 14, 2023

Savara Announces New Leadership Appointments

January 20, 2023

Savara Announces New Employment Inducement Grant

November 22, 2022

Savara Announces New Employment Inducement Grant

November 10, 2022

Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

November 09, 2022

Savara to Participate in Three Upcoming Investor Conferences

September 14, 2022

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

September 06, 2022

Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022

September 01, 2022

Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference

August 26, 2022

Savara Announces Resignation of Chief Medical Officer

August 25, 2022

Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

August 11, 2022

Savara Reports Second Quarter 2022 Financial Results and Provides Business Update

July 11, 2022

Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022

June 16, 2022

Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic

June 01, 2022

Savara to Present at Jefferies Healthcare Conference

May 17, 2022

Savara to Present at H.C. Wainwright Global Investment Conference

May 11, 2022

Savara Reports First Quarter 2022 Financial Results and Provides Business Update

April 26, 2022

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

April 22, 2022

Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank

March 30, 2022

Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update

March 16, 2022

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

March 09, 2022

Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference

January 04, 2022

Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

December 02, 2021

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

November 15, 2021

Savara to Participate in Two Upcoming Investor Healthcare Conferences

November 12, 2021

Savara Reports Third Quarter 2021 Financial Results and Provides Business Update

November 10, 2021

Savara to Present at the Jefferies London Healthcare Conference

October 07, 2021

Savara to Present at the Inaugural Piper Sandler Lung Day

September 07, 2021

Savara to Participate in Two Upcoming Investor Healthcare Conferences

September 03, 2021

Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 20, 2021

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

August 12, 2021

Savara Reports Second Quarter 2021 Financial Results and Provides Business Update

June 30, 2021

Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

May 26, 2021

Savara to Present at the Jefferies Virtual Healthcare Conference

May 17, 2021

Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit

May 14, 2021

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

May 13, 2021

Savara Reports First Quarter 2021 Financial Results and Provides Business Update

March 15, 2021

Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters’ Option

March 11, 2021

Savara Announces Pricing of Public Offering of Common Stock

March 10, 2021

Savara Announces Proposed Public Offering of Common Stock

December 10, 2020

Savara Provides Pipeline and Business Update

November 24, 2020

Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences

November 11, 2020

Savara to Present at the Jefferies Virtual London Healthcare Conference

November 05, 2020

Savara Reports Third Quarter 2020 Financial Results and Provides Business Update

September 11, 2020

Savara Announces Senior Management Changes

September 09, 2020

Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually

September 08, 2020

Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results

September 03, 2020

Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)

August 06, 2020

Savara Reports Second Quarter 2020 Financial Results and Provides Business Update

August 05, 2020

Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually

July 30, 2020

Savara to Report Second Quarter 2020 Financial Results and Provide Business Update

May 27, 2020

Savara to Present at the Jefferies Virtual Healthcare Conference

May 08, 2020

Savara Announces Change of Date for 2020 Annual Meeting of Stockholders

May 07, 2020

Savara Reports First Quarter 2020 Financial Results and Provides Business Update

April 30, 2020

Savara to Report First Quarter 2020 Financial Results and Provide Business Update

April 02, 2020

Savara Obtains Global Rights to Develop and Commercialize Apulmiq

March 30, 2020

Savara Provides Business Update in Response to COVID-19 Pandemic

March 12, 2020

Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update

March 05, 2020

Savara to Report Fourth Quarter/Year-End 2019 Financial Results and Provide Business Update

December 30, 2019

Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

December 20, 2019

Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million

December 03, 2019

Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors

November 27, 2019

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

November 26, 2019

Savara’s COO and CMO to Present at the Evercore ISI 2nd Annual HealthCONx Conference

November 18, 2019

Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer

November 12, 2019

Savara to Present at the Stifel 2019 Healthcare Conference

November 07, 2019

Savara Reports Third Quarter 2019 Financial Results and Provides Business Update

October 31, 2019

Savara to Report Third Quarter 2019 Financial Results and Provide Business Update

October 02, 2019

Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program

September 18, 2019

Savara to Present Comprehensive Data From Pivotal Phase 3 IMPALA Study at 2019 ERS

August 08, 2019

Savara Reports Second Quarter 2019 Financial Results and Provides Business Update

August 01, 2019

Savara to Report Second Quarter 2019 Financial Results and Provide Business Update

July 31, 2019

Savara to Present at the 39th Annual Canaccord Genuity Global Growth Conference

June 13, 2019

Savara to Present at the JMP Securities Life Sciences Conference

June 12, 2019

Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)

May 09, 2019

Savara Reports First Quarter 2019 Financial Results and Provides Business Update

May 06, 2019

Savara Announces Molgradex Received Fast Track Designation by FDA for Treatment of Autoimmune Pulmonary Alveolar Proteinosis

May 02, 2019

Savara to Report First Quarter 2019 Financial Results and Provide Business Update

April 02, 2019

Savara To Present at the H.C. Wainwright Global Life Sciences Conference in London

April 01, 2019

Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection in People Living with Cystic Fibrosis

March 13, 2019

Savara Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update

March 06, 2019

Savara To Report Q4/Year-End 2018 Financial Results And Business Update On March 13, 2019

March 04, 2019

Savara to Present at the 39th Annual Cowen and Company Healthcare Conference

February 06, 2019

Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies

December 19, 2018

Savara Announces Interim Results for OPTIMA Clinical Study of Molgradex for the Treatment of NTM

November 16, 2018

Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th

November 07, 2018

Savara Reports Third Quarter 2018 Financial Results and Provides Business Update

November 01, 2018

Savara to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 7, 2018

October 31, 2018

Savara Completes Enrollment in Molgradex OPTIMA Clinical Study for the Treatment of NTM

October 15, 2018

Savara Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP

September 27, 2018

Savara Provides Enrollment Update on Molgradex Impala and OPTIMA Clinical Studies and Reaffirms Guidance for Topline Data

August 27, 2018

Savara Becomes Inaugural Foundation Sponsor of the PAP Foundation

August 09, 2018

Savara Reports Second Quarter 2018 Financial Results and Provides Positive Business Update

August 02, 2018

Savara to Host Second Quarter 2018 Financial Results and Business Update Conference Call on Thursday, August 9, 2018

July 26, 2018

Savara Announces Pricing of Public Offering of Common Stock

July 25, 2018

Savara Announces Proposed Public Offering of Common Stock

July 25, 2018

Savara Provides Positive Update on Development and Commercial Preparations of Molgradex, Including Expansion into NTM In CF

July 23, 2018

Savara to Ring Nasdaq Stock Market Opening Bell on July 23rd

June 25, 2018

Savara Joins Russell 3000® Index

June 13, 2018

Savara to Present at JMP Securities 2018 Life Sciences Conference on June 20th

May 29, 2018

Savara Provides Update on Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria Infection

May 15, 2018

UPDATE -- Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 15th

May 11, 2018

Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 15th

May 09, 2018

Savara Reports First Quarter 2018 Financial Results and Provides Business Update

May 01, 2018

Savara to Host First Quarter 2018 Financial Results and Business Update Conference Call on Wednesday, May 9, 2018

March 15, 2018

Savara to Present at 28th Annual Oppenheimer & Co. Healthcare Conference on March 20th

March 14, 2018

Savara Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

March 13, 2018

Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection

March 11, 2018

Aironite Fails to Meet Primary Endpoint in the Indie Phase 2 Clinical Study Conducted by the Heart Failure Clinical Research Network

March 07, 2018

Savara to Host Fourth Quarter & Fiscal Year End 2017 Financial Results and Business Update Conference Call on Wednesday March 14, 2018

February 16, 2018

Top Line Results From Aironite Phase 2 Clinical Trial for the Treatment of HFpEF to Be Presented at American College of Cardiology 67th Annual Scientific Sessions & Expo on March 11th

February 12, 2018

Savara Announces IND Approval for Expansion of Molgradex Phase 3 Study Into U.S.

February 06, 2018

Savara Reports Publication of Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria

February 05, 2018

Savara to Present at the 20th Annual BIO CEO & Investor Conference on February 12th

January 04, 2018

Savara Announces Appointment of Peter Ginsberg as Vice President of Business Development

December 21, 2017

Savara Submits Investigational New Drug Application to FDA for Expansion of Molgradex Impala Study Into U.S.

December 18, 2017

Savara Added to Nasdaq Biotechnology Index

November 29, 2017

Savara Receives $5 Million Award From Cystic Fibrosis Foundation Therapeutics, Inc. for the Development of AeroVanc

November 13, 2017

Savara to Present at the Jefferies 2017 London Healthcare Conference on November 16th

November 08, 2017

Savara Reports Third Quarter 2017 Financial Results and Provides Business Update

November 01, 2017

Savara to Host Third Quarter 2017 Financial Results and Business Update Conference Call on Wednesday November 8, 2017

October 25, 2017

Savara Announces Pricing of Public Offering of Common Stock

October 24, 2017

Savara Announces Proposed Public Offering of Common Stock

October 24, 2017

Savara Announces Expansion of Molgradex Development to Include Treatment of Nontuberculous Mycobacterial (NTM) Lung Infection

October 19, 2017

Savara Announces Uplisting to the Nasdaq Global Select Market(R)

October 18, 2017

Savara Reports Completion of Enrollment in Phase 2 Clinical Trial of Aironite for the Treatment of HFpEF

September 26, 2017

Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc

September 21, 2017

Savara to Present at the Cantor Fitzgerald 2017 Global Healthcare Conference on September 27th

September 05, 2017

Savara to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 11th

August 09, 2017

Savara Reports Second Quarter 2017 Financial Results and Provides Business Update

July 11, 2017

Positive Interim Results Of Aironite Phase 2 Study Presented At 4th Annual Drug Discovery And Development Symposium For Pulmonary Hypertension

June 20, 2017

Savara Set To Join Russell Microcap® Index

June 07, 2017

Savara Announces Closing Of Public Offering Of Common Stock

June 05, 2017

Savara To Present At The Jefferies 2017 Global Healthcare Conference On June 9th

June 02, 2017

Savara Announces Pricing Of Public Offering Of Common Stock

June 01, 2017

Savara Announces Proposed Public Offering Of Common Stock

May 10, 2017

Savara Announces Expedited U.S. Molgradex Development Strategy

May 08, 2017

Savara Announces Issuance Of U.S. Composition Of Matter Patent Covering AeroVanc

May 01, 2017

Savara Secures $15 Million Loan And Security Agreement With Silicon Valley Bank

April 27, 2017

Savara Announces Closing Of Merger With Mast Therapeutics

April 25, 2017

Mast Therapeutics And Savara Announce Anticipated Merger Exchange Ratio

April 21, 2017

Mast Therapeutics Announces Adjournment Of Special Stockholders Meeting

April 20, 2017

Mast Therapeutics Announces Possible Adjournment Of Special Stockholders Meeting To Solicit Additional Votes For Merger With Savara

April 17, 2017

Mast Reminds Stockholders To Vote For The Proposed Merger With Savara

April 11, 2017

Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Mast Therapeutics Stockholders Vote "FOR" The Proposed Merger And Related Proposals

April 10, 2017

Mast Therapeutics And Savara Announce Approval To List Common Stock On The Nasdaq Capital Market

March 16, 2017

Mast Therapeutics Sets Date For Special Meeting Of Stockholders To Vote On Proposed Merger With Savara

March 06, 2017

Mast Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results

March 06, 2017

Mast Therapeutics Announces Clinical Study Of AIR001 For The Treatment Of Chronic Infection In Cystic Fibrosis Patients

January 07, 2017

Mast Therapeutics And Savara Sign Merger Agreement

December 06, 2016

Mast Therapeutics Announces Initiation Of Patient Enrollment In Additional Phase 2 Study Of AIR001 For The Treatment Of Heart Failure With Preserved Ejection Fraction

November 21, 2016

Mast Therapeutics Provides Update On Strategic Direction

November 08, 2016

Mast Therapeutics Reports Third Quarter 2016 Financial Results

November 03, 2016

Positive Interim Results From Phase 2 Study Of AIR001 In Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction (PH-HFpEF) Published In Journal Of Clinical Investigation

November 02, 2016

Savara Pharmaceuticals appoints David L. Lowrance as CFO

November 01, 2016

Mast Therapeutics To Host Third Quarter 2016 Financial Results And Business Update Conference Call

October 17, 2016

Mast Therapeutics Announces Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001

October 13, 2016

Mast Therapeutics To Present At 2016 BIO Investor Forum On October 19th

September 26, 2016

Mast Therapeutics Provides Business Update

September 20, 2016

Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell Disease

September 06, 2016

Mast Therapeutics Joins New Sickle Cell Disease Coalition, Supports Campaign To Improve Treatment And Care

September 01, 2016

Mast Therapeutics To Present At 18th Annual Rodman & Renshaw Global Investment Conference On September 13th

August 09, 2016

Mast Therapeutics Reports Second Quarter 2016 Financial Results

August 08, 2016

Mast Therapeutics Awarded Small Business Innovation Research Grant From The National Institutes Of Health

August 03, 2016

Mast Therapeutics Announces Issuance Of Composition Of Matter Patent Covering Vepoloxamer

August 02, 2016

Mast Therapeutics To Present At 36th Annual Canaccord Genuity Growth Conference On August 10

August 01, 2016

Mast Therapeutics Announces Initiation Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network

July 18, 2016

Savara Completes Acquisition of Serendex

June 21, 2016

Savara Pharmaceuticals Acquires Serendex Pharmaceuticals

June 09, 2016

Savara Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference

June 08, 2016

Mast Therapeutics Receives Notice Of Allowance Of Composition Of Matter Patent Application Covering Vepoloxamer

May 25, 2016

First patient dosed in Savara’s pivotal trial for PAP

May 23, 2016

Results of Vepoloxamer Nonclinical Studies in Advanced Heart Failure Presented at European Society of Cardiology 3rd World Congress on Acute Heart Failure

May 16, 2016

Positive Interim Results From Second Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Presented At American Thoracic Society International Conference

May 12, 2016

Savara signs license agreement with Japanese partner

May 06, 2016

Mast Therapeutics Reports First Quarter 2016 Financial Results And Recent Highlights

April 13, 2016

Mast Therapeutics Announces Agreement For Phase 2 Study Of AIR001 To Be Conducted By The Heart Failure Clinical Research Network

April 04, 2016

Results Of Vepoloxamer Nonclinical Studies In Advanced Heart Failure Presented At American College Of Cardiology 65th Annual Scientific Sessions & Expo

March 14, 2016

Mast Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results

March 01, 2016

Savara Pharmaceuticals Completes $20 Million Round of Financing

March 01, 2016

Mast Therapeutics To Present At Cowen And Company 36th Annual Health Care Conference On March 7th

February 29, 2016

Mast Announces Amendment To Loan And Security Agreement With Hercules Capital

February 22, 2016

Mast Therapeutics Completes Patient Enrollment In Pivotal Phase 3 "EPIC" Study For The Treatment Of Sickle Cell Crisis

February 16, 2016

Mast Therapeutics Closes $8 Million Public Offering

February 10, 2016

Mast Therapeutics Announces Pricing Of Underwritten Public Offering

February 09, 2016

Mast Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants

February 02, 2016

Mast Therapeutics To Present At 2016 BIO CEO & Investor Conference On February 8th

February 01, 2016

Mast Therapeutics' AIR001 Selected By The Heart Failure Clinical Research Network For Evaluation In A 100-Patient Multicenter Phase 2 Study

February 01, 2016

Mast Therapeutics Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic

January 07, 2016

Mast Therapeutics Provides Business Update

November 24, 2015

Mast Therapeutics To Present At The Piper Jaffray 27th Annual Healthcare Conference

November 16, 2015

Vepoloxamer Data Selected For Presentation At 57th Annual American Society Of Hematology (ASH) Meeting

November 12, 2015

Mast Therapeutics Reports Third Quarter 2015 Financial Results

November 09, 2015

Vepoloxamer Nonclinical Study Results In Advanced Heart Failure To Be Presented At 2015 American Heart Association Scientific Sessions

November 09, 2015

Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board of Directors

November 02, 2015

Mast Therapeutics Announces Appointment Of Matthew Pauls To Board Of Directors

October 29, 2015

Mast Therapeutics To Host Third Quarter 2015 Financial Results And Corporate Update Conference Call

October 26, 2015

Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

October 13, 2015

BASF to Develop a High Purity Poloxamer for Mast Therapeutics

September 30, 2015

Mast Announces Amendment To Loan And Security Agreement With Hercules Technology Growth Capital

September 28, 2015

Mast Announces Presentation Of Results Of Nonclinical Study Of Vepoloxamer In Chronic Heart Failure At The HFSA's Annual Scientific Meeting

September 23, 2015

Mast Therapeutics To Host Analyst & Investor Day On October 7, 2015

August 12, 2015

Mast Therapeutics Reports Second Quarter 2015 Financial Results

August 06, 2015

Mast Therapeutics To Host Second Quarter 2015 Financial Results And Corporate Update Conference Call

May 28, 2015

Mast Therapeutics Announces Change In Board Of Directors

May 26, 2015

Mast Therapeutics Announces Initiation Of EPIC-E Study

May 11, 2015

Mast Therapeutics Reports First Quarter 2015 Financial Results

April 21, 2015

Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark

April 09, 2015

Mast To Present New Data Supporting Vepoloxamer (MST-188) In Sickle Cell Disease At 9th Annual Sickle Cell Disease Research And Education Symposium And 38th National Sickle Cell Disease Scientific Meeting

March 24, 2015

Mast Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results

March 23, 2015

Mast To Develop Vepoloxamer (MST-188) In Chronic Heart Failure

March 02, 2015

Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure

February 24, 2015

Mast Therapeutics To Present At Cowen And Company's 35th Annual Healthcare Conference On March 2nd

February 23, 2015

Savara Pharmaceuticals’ AeroVanc Meets Primary Endpoint of MRSA Reduction in Phase 2 Trial in People with Cystic Fibrosis

February 11, 2015

Mast Therapeutics Announces New Data Supporting Vepoloxamer In Embolic Stroke

February 04, 2015

Mast Therapeutics Announces Initiation Of Phase 2a Studies Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

February 03, 2015

Mast Therapeutics To Present At 17th Annual BIO CEO & Investor Conference On February 9th

January 24, 2015

Mast Therapeutics Announces Management Change

January 07, 2015

Mast Therapeutics To Present At 2015 Biotech Showcase Conference On January 12th

January 05, 2015

Mast Therapeutics Provides Update On Epic Study Enrollment And 2015 Milestones

December 30, 2014

Mast Therapeutics To Host Corporate Conference Call

December 09, 2014

Mast Announces Plans For Development Of Vepoloxamer (MST-188) In Heart Failure

November 26, 2014

Mast Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference On December 3rd

November 19, 2014

New Data From Nonclinical Heart Failure Study To Be Presented At American Heart Association Conference

November 17, 2014

Mast Therapeutics To Present MST-188 Data At 2014 American Society Of Hematology Conference

November 13, 2014

Mast Therapeutics Announces Closing Of Underwritten Public Offering

November 06, 2014

Mast Therapeutics Announces Pricing Of Underwritten Public Offering

November 05, 2014

Mast Therapeutics Announces Underwritten Public Offering

October 31, 2014

Mast Therapeutics Reports Third Quarter 2014 Financial Results

October 02, 2014

Mast Therapeutics Announces Appointment Of Chief Medical Officer

September 08, 2014

Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan

September 02, 2014

Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th

August 29, 2014

Mast Therapeutics Announces Management Change

August 11, 2014

Mast Therapeutics Provides Corporate Update And Reports Second Quarter 2014 Financial Results

August 07, 2014

Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th

June 19, 2014

Mast Announces Appointment Of Howard C. Dittrich M.D. To Board of Directors

June 16, 2014

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

May 05, 2014

Mast Therapeutics Reports First Quarter 2014 Financial Results

April 14, 2014

Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease

March 26, 2014

Mast Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results

March 26, 2014

Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia

March 11, 2014

Purified Poloxamer Granted Unique Nonproprietary Name (Vepoloxamer) By U.S. Adopted Names Council

February 27, 2014

Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.

February 25, 2014

Mast Therapeutics To Present At The Cowen & Co. 34th Annual Healthcare Conference On March 3rd

February 24, 2014

Mast Therapeutics Announces International Expansion Of Phase 3 "EPIC" Study Of MST-188

February 18, 2014

Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study

February 10, 2014

Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.

January 08, 2014

Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188

January 07, 2014

Mast Therapeutics To Present At The OneMedForum Emerging Company Finance Conference On January 14

January 06, 2014

Mast Therapeutics Announces Positive Data In Model Of Heart Failure

November 26, 2013

Mast Therapeutics To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 3

November 13, 2013

FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia

November 04, 2013

Mast Therapeutics Reports Third Quarter 2013 Financial Results

October 01, 2013

Mast Therapeutics To Present At The 12th Annual BIO Investor Forum On October 8

September 30, 2013

Mast Therapeutics To Present At The Leerink Swann Rare Disease Roundtable On October 2

September 06, 2013

Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013

September 03, 2013

Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10

August 05, 2013

Mast Therapeutics Reports Second Quarter 2013 Financial Results

July 23, 2013

Mast Therapeutics Reports Results From Clinical QT Study Of MST-188

July 03, 2013

Mast Therapeutics To Present At The JMP Securities Healthcare Conference On July 9

June 14, 2013

Mast Therapeutics Prices Public Offering Of Units

May 15, 2013

Mast Therapeutics Reports First Quarter 2013 Financial Results

April 17, 2013

Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium

March 28, 2013

Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188

March 25, 2013

European Commission Designates MST-188 As An Orphan Medicinal Product

March 19, 2013

Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results

March 11, 2013

ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"

February 28, 2013

ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"

February 28, 2013

Adventrx To Develop ANX-188 For Complications Of Arterial Disease

February 26, 2013

ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications

February 25, 2013

ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4

February 11, 2013

ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188

February 05, 2013

ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12

January 30, 2013

ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188

January 04, 2013

ADVENTRX Announces Appointment of Chief Financial Officer

January 02, 2013

ADVENTRX To Present At The 6th Annual OneMedForum Emerging Company Finance Conference On January 8

December 19, 2012

ADVENTRX To Initiate Phase 3 Study Of ANX-188

December 03, 2012

ADVENTRX Announces Launch Of New Corporate Website

November 05, 2012

ADVENTRX Reports Third Quarter 2012 Financial Results

October 25, 2012

ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188

October 23, 2012

ADVENTRX Announces Conference Call To Review Protocol For Phase 3 Clinical Study Of ANX-188

October 02, 2012

ADVENTRX Engages Theradex Systems, Inc. to Manage Phase 3 Clinical Study of ANX-188

September 07, 2012

ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors

August 28, 2012

ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10

August 14, 2012

ADVENTRX Announces Appointment Of Chief Medical Officer

August 06, 2012

ADVENTRX Reports Second Quarter 2012 Financial Results

July 26, 2012

ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference

July 11, 2012

ADVENTRX APPLAUDS INCLUSION OF RARE DISEASES PROVISIONS IN THE FDA SAFETY AND INNOVATION ACT

July 09, 2012

ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12

June 26, 2012

ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product

June 18, 2012

ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum

June 12, 2012

ADVENTRX And Pierre Fabre Announce Manufacturing Agreement For ANX-188 Drug Substance

May 07, 2012

ADVENTRX Reports First Quarter 2012 Financial Results

April 16, 2012

ADVENTRX Pharmaceuticals to Sponsor & Present at the Martin Center's 2012 Sickle Cell Disease Conference

April 09, 2012

ADVENTRX Announces Establishment of Regulatory Advisory Board

March 15, 2012

ADVENTRX CEO Selected by Combined Health Agencies as a 2012 Health Hero

March 07, 2012

ADVENTRX Reports Fourth Quarter and Full Year 2011 Financial Results

February 07, 2012

ADVENTRX Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 14

December 01, 2011

ADVENTRX Meets with FDA to Discuss Development Plans for ANX-188

November 16, 2011

ADVENTRX Announces Closing of Public Offering

November 11, 2011

ADVENTRX Prices Public Offering of Stock

November 10, 2011

ADVENTRX Announces Public Offering of Stock

November 07, 2011

ADVENTRX Reports Third Quarter 2011 Financial Results

October 26, 2011

ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514

October 19, 2011

ADVENTRX Pharmaceuticals to Present at the 10th Annual BIO Investor Forum Conference on October 26

September 30, 2011

ADVENTRX Announces Results of FDA Meeting to Discuss Exelbine NDA

September 06, 2011

ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12

August 30, 2011

ADVENTRX Provides Update on All Three Pipeline Products

August 09, 2011

ADVENTRX Receives Complete Response Letter for Exelbine NDA

August 08, 2011

ADVENTRX Reports Second Quarter 2011 Financial Results

August 04, 2011

ADVENTRX Pharmaceuticals to Present at the 31st Annual Canaccord Genuity Growth Conference on August 11

July 25, 2011

ADVENTRX Announces Appointment of Senior Vice President, Commercial

June 16, 2011

ADVENTRX Pharmaceuticals to Present at the OneMedForum Business Development and Investment Conference on June 23

Explore events and presentations

See upcoming events